Failure of testes to produce adequate testosterone, spermatozoa, or both — primary (testicular) or secondary (pituitary/hypothalamic).
Also known as: male hypogonadism, low testosterone, low T, androgen deficiency, testosterone deficiency, hypogonadotropic hypogonadism, Klinefelter syndrome, Kallmann syndrome
Overview
Clinical syndrome resulting from failure of the testes to produce physiologic levels of testosterone (androgen deficiency) and/or normal numbers of spermatozoa due to disruption at one or more levels of the hypothalamic-pituitary-testicular axis. Classified as primary (hypergonadotropic; testicular failure) or secondary (hypogonadotropic; hypothalamic-pituitary disease), with combined forms also occurring.
Epidemiology
Prevalence rises with age and comorbidity. Approximately 2-6% of adult men have symptomatic hypogonadism; prevalence reaches 20-50% in men with obesity, type 2 diabetes, or chronic opioid use. Klinefelter syndrome (47,XXY) is the most common primary hypogonadism, affecting ~1 in 600 live male births.
Try two board-style Male Hypogonadism questions
Real questions from the FirstPassPA bank, with the full explanation. Pick an answer — no signup, no email.
Question 1EndocrineMedium
A 38-year-old man presents with low libido, erectile dysfunction, and fatigue for 8 months. He also reports decreased morning erections and difficulty concentrating at work. PMH is unremarkable and he takes no medications. Exam shows small soft testes, decreased body hair, and mild gynecomastia. An 8 AM total testosterone drawn fasting is 180 ng/dL (normal 300-1000), confirmed low on a repeat morning sample. Which of the following is the most appropriate next step in his evaluation?
AKaryotype analysis
BPituitary MRI with contrast
CSerum estradiol and DHEA-S
DSerum LH and FSH levels
Reveal answer & full explanation
Correct answer: D — Serum LH and FSH levels
AKaryotype analysis
BPituitary MRI with contrast
CSerum estradiol and DHEA-S
DSerum LH and FSH levels✓
Why Serum LH and FSH levels is correct
Biochemically confirmed hypogonadism requires two early-morning total testosterone measurements, which this patient has
The next step is to determine whether the defect is primary (testicular) or secondary (hypothalamic-pituitary) by measuring LH and FSH
This LH/FSH branch point determines all downstream testing
Why the others are wrong
Serum estradiol and DHEA-S — do not localize the lesion and are not part of initial hypogonadism workup; buzzword trap pulling in unrelated sex-steroid labs
Karyotype analysis — appropriate only after primary hypogonadism with elevated FSH is documented and Klinefelter syndrome is suspected; right-test-wrong-step before gonadotropins are known
Pituitary MRI with contrast — reserved for confirmed secondary hypogonadism, particularly with markedly low testosterone (<150 ng/dL), elevated prolactin, visual field defects, or other anterior pituitary hormone abnormalities, not before LH/FSH are known; anchoring on the central-cause possibility before localizing
Question 2EndocrineMedium
A 58-year-old man presents with decreased libido, fatigue, and morning erections lost over the past year. Two early-morning total testosterone levels are 180 ng/dL and 195 ng/dL (normal 300–1000), with low LH and FSH, consistent with hypogonadism. He has a history of hypertension and a hematocrit of 49%. He asks about starting testosterone replacement therapy and wants to know what to monitor. Which of the following is a recognized risk of testosterone replacement therapy?
AHypocalcemia
BErythrocytosis
CAdrenal insufficiency
DHyperthyroidism
Reveal answer & full explanation
Correct answer: B — Erythrocytosis
AHypocalcemia
BErythrocytosis✓
CAdrenal insufficiency
DHyperthyroidism
Why Erythrocytosis is correct
Exogenous testosterone stimulates renal erythropoietin production and bone marrow erythropoiesis, leading to dose-dependent increases in hemoglobin and hematocrit
Endocrine Society guidelines recommend checking a baseline hematocrit and rechecking at 3–6 months and annually; therapy should be held if hematocrit exceeds 54% because of thromboembolic risk
This patient's baseline hematocrit of 49% makes him particularly susceptible
Other recognized risks include worsening of obstructive sleep apnea, acne, gynecomastia, fluid retention, suppression of spermatogenesis with infertility, and growth of pre-existing prostate cancer
Why the others are wrong
A) Hypocalcemia — not a recognized effect of testosterone; consider PTH, vitamin D, or calcimimetic-related causes instead
C) Adrenal insufficiency — testosterone replacement therapy does not suppress the HPA axis; glucocorticoids do
D) Hyperthyroidism — testosterone replacement therapy does not alter thyroid function in any clinically significant way
Additional high-yield points
PSA, hematocrit, and symptom assessment are the core testosterone replacement therapy monitoring trio
🔒 Free preview limit reached
Keep reading — start your free trial
You've read your 2 free diagnosis previews. Create your free account to unlock the full Male Hypogonadism outline — plus all 514 diagnoses, 6,500+ board-style questions, flashcards, and an AI tutor. Your 7-day free trial includes everything, and there's no credit card required.
Functional secondary: chronic opioid use, glucocorticoid therapy, obesity (BMI >30), type 2 diabetes, metabolic syndrome, obstructive sleep apnea, chronic systemic illness, anabolic steroid use and withdrawal
Anabolic-androgenic steroid abuse with subsequent hypothalamic-pituitary-testicular suppression
Pathophysiology
Testosterone production by Leydig cells is driven by pulsatile LH from the pituitary, itself stimulated by pulsatile GnRH from the hypothalamus. Sertoli cell function (spermatogenesis, inhibin B secretion) requires FSH and intratesticular testosterone. Disruption at the testes (Leydig and seminiferous tubule failure) elevates LH and FSH (primary hypogonadism). Disruption at the hypothalamus or pituitary lowers LH and FSH despite low testosterone (secondary hypogonadism). Obesity contributes via increased aromatase activity (testosterone → estradiol), increased estrogen-mediated negative feedback, and decreased SHBG.
Depression — Anhedonia, low mood, sleep and appetite changes overlap with hypogonadism; normal testosterone or borderline; mood improves with treatment of depression alone
Hypothyroidism — Fatigue, weight gain, decreased libido; elevated TSH; resolves with thyroid hormone replacement
Anemia of chronic disease — Fatigue and low energy; CBC and iron studies; treat underlying cause
Kallmann syndrome (specific secondary cause) — Congenital secondary hypogonadism with anosmia or hyposmia; failure of GnRH neuron migration; small testes, eunuchoid proportions
Diagnostic workup
Diagnostic criteria
Two morning total testosterone values below the laboratory reference range (typically <264 ng/dL) in a man with symptoms or signs consistent with androgen deficiency, plus determination of primary versus secondary form by LH and FSH.
Labs
Total testosterone — collected fasting between 7-10 AM on two separate mornings (testosterone is diurnal and food-affected); confirm low (<264 ng/dL by Endocrine Society 2018 threshold) before further evaluation
If borderline or altered SHBG (obesity, aging, diabetes, hyperthyroidism, liver disease): free testosterone by equilibrium dialysis or calculated free testosterone with SHBG
LH and FSH — high suggests primary, low or inappropriately normal suggests secondary
Prolactin in all secondary cases (rule out prolactinoma)
Iron studies (ferritin, transferrin saturation) — hemochromatosis
Estradiol if gynecomastia or prior to estradiol-modulating therapy
Karyotype if small firm testes and elevated gonadotropins (suspected Klinefelter)
Semen analysis if fertility concerns
Imaging
MRI of the sella with gadolinium for confirmed secondary hypogonadism, severe hypogonadism (testosterone <150 ng/dL), hyperprolactinemia, or any pituitary symptoms
DEXA scan to assess bone mineral density at baseline in chronic hypogonadism
Often irreversible; consider ART with retrieved sperm
hCG + FSH, clomiphene, or pulsatile GnRH
Primary versus secondary male hypogonadism — distinguishing features and treatment implications.
Treatment
First-line
Address reversible causes: weight loss in obesity, opioid taper, treat OSA with CPAP, discontinue offending agents (chronic glucocorticoids, anabolic steroids)
Testosterone replacement — testosterone cypionate IM (100-200 mg every 1-2 weeks), testosterone gel (1% or 1.62% applied to upper arms or shoulders daily), intranasal testosterone (Natesto, three times daily), testosterone enanthate IM, transdermal patch, subcutaneous testosterone enanthate auto-injector, or testosterone undecanoate pellets
Treat underlying pituitary or hypothalamic disease (transsphenoidal surgery for macroadenoma, dopamine agonist for prolactinoma)
Second-line / adjunct
Fertility preservation: human chorionic gonadotropin (hCG) with or without recombinant FSH (follitropin alfa, follitropin beta) — preferred over exogenous testosterone if fertility desired, since testosterone suppresses spermatogenesis
SERM (clomiphene citrate, off-label) — for secondary hypogonadism in men who wish to preserve fertility; raises endogenous LH/FSH/testosterone without suppressing spermatogenesis
Aromatase inhibitor — anastrozole — selected obese men with high estradiol and persistent symptoms despite testosterone (limited evidence)
Pulsatile GnRH via pump — congenital hypogonadotropic hypogonadism (Kallmann), particularly for fertility induction
Complications
Osteoporosis and low-trauma fractures
Sarcopenia, frailty, and falls in older men
Infertility
Metabolic syndrome, type 2 diabetes (bidirectional relationship)
Depression and decreased quality of life
Testosterone replacement risks: erythrocytosis (hematocrit >54%), worsening obstructive sleep apnea, acne, fluid retention, suppression of spermatogenesis (paradoxical infertility), gynecomastia from aromatization, possible increased cardiovascular risk in selected high-risk men
PANCE pearls
Never diagnose hypogonadism on a single afternoon testosterone — confirm with two morning (7-10 AM) fasting samples; values fluctuate diurnally and post-prandially.
Testosterone replacement SUPPRESSES spermatogenesis by inhibiting LH and FSH — men of reproductive age who wish to preserve fertility should be treated with hCG (with or without FSH) or clomiphene rather than exogenous testosterone.
Monitor hematocrit (stop or reduce dose if >54%), PSA in men over 40, and lipid panel during testosterone replacement; obtain a baseline DEXA scan.
Klinefelter syndrome is widely under-recognized — consider karyotype in any man with primary hypogonadism, infertility, gynecomastia, or learning difficulty.
Functional secondary hypogonadism (obesity, opioids, OSA, glucocorticoids) often resolves with treatment of the underlying condition — testosterone replacement is not always the answer.
References
Endocrine Society 2018 — Testosterone Therapy in Men with Hypogonadism: An Endocrine Society Clinical Practice Guideline (Bhasin et al., J Clin Endocrinol Metab 2018)
AUA 2018 — American Urological Association Guideline on the Evaluation and Management of Testosterone Deficiency (Mulhall et al., J Urol 2018)
AACE 2002 — American Association of Clinical Endocrinologists Medical Guidelines for Clinical Practice for the Evaluation and Treatment of Hypogonadism in Adult Male Patients (Petak et al., Endocr Pract 2002)
TRAVERSE Trial — Cardiovascular Safety of Testosterone-Replacement Therapy (Lincoff et al., NEJM 2023)
Practice Endocrinology questions on FirstPassPA
Turn this outline into retention. 6,500+ board-style questions with an AI tutor that explains every answer — free to start, no card required.
Educational use only. This outline is a study aid for PA students and is not medical advice or a substitute for clinical judgment. FirstPassPA is an independent study tool and is not affiliated with, endorsed by, or sponsored by NCCPA or PAEA. PANCE® and PANRE® are registered trademarks of the National Commission on Certification of Physician Assistants; End of Rotation™ is a program of the Physician Assistant Education Association.